Trial Profile
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Carcinoma; Malignant-mesothelioma
- Focus Adverse reactions
- 08 Mar 2024 Primary endpoint has been amended and Trial Focus has been shifted to Ar.
- 23 Sep 2023 Planned End Date changed from 24 Oct 2023 to 21 Sep 2024.
- 25 Oct 2022 Planned End Date changed from 1 Oct 2022 to 24 Oct 2023.